| Literature DB >> 33073217 |
Mirja Mittermaier1,2, Philipp Pickerodt3, Florian Kurth1, Laure Bosquillon de Jarcy1, Alexander Uhrig1, Carmen Garcia1, Felix Machleidt1, Panagiotis Pergantis1, Susanne Weber1, Yaosi Li1, Astrid Breitbart1, Felix Bremer1, Philipp Knape1, Marc Dewey2,4, Felix Doellinger4, Steffen Weber-Carstens3, Arthur S Slutsky5,6, Wolfgang M Kuebler6,7,8, Norbert Suttorp1, Holger Müller-Redetzky1,9.
Abstract
BACKGROUND: In face of the Coronavirus Disease (COVID)-19 pandemic, best practice for mechanical ventilation in COVID-19 associated Acute Respiratory Distress Syndrome (ARDS) is intensely debated. Specifically, the rationale for high positive end-expiratory pressure (PEEP) and prone positioning in early COVID-19 ARDS has been questioned.Entities:
Year: 2020 PMID: 33073217 PMCID: PMC7547915 DOI: 10.1016/j.eclinm.2020.100579
Source DB: PubMed Journal: EClinicalMedicine ISSN: 2589-5370
Fig. 1Study cohort flowchart. A, The first consecutive 23 COVID-19 patients treated on our ICU were enrolled to this study, investigating PEEP and prone positioning in mechanically ventilated patients. Eight patients were excluded from the assessment of the specific interventions as they received ECMO therapy (three patients, ECMO therapy would interfere with the analysis of oxygenation), or high-flow oxygen therapy but no mechanical ventilation (five patients that could not be asses regarding the effects of invasive mechanical ventilation, PEEP and prone positioning), resulting in 15 patients eligible for this study. Ten patients were intubated in our ICU (Subset 1, intubation group), while eight patients were transferred intubated to our ward. For seven of the 15 mechanically ventilated patients, a full dataset of decremental PEEP trials was available and they were accordingly included in Subset 2 (PEEP trial analysis) for determination of optimal PEEP. Nine of the fifteen patients were subject to prone positioning (Subset 3, prone position analysis). B, Illustration of the allocation of the 15 patients to each analysis.
Demographic and clinical characteristics of the patients.
| Demographic and clinical characteristics of the patients | |
|---|---|
| Characteristics | |
| Patients | |
| Age (years) | 62·1 ± 14·1 |
| Age (range) | 26 - 81 |
| Sex - Male (%) | 73·9 |
| BMI, kg/m2 | 29·3 ± 4·8 |
| Mean duration of symptoms before admission (days) | 6·4 ± 3·2 |
| Mean duration of symptoms before intubation (days) | 7·6 ± 3·7 |
| Number of patients with high-flow nasal oxygen (no intubation) | 5 |
| Number of patients with ECMO | 3 |
| Hospital mortality rate (%) * | 29·2 |
| Hospital mortality rate of patients with high-flow nasal oxygen (%) | 20·0 |
| Hospital mortality rate of ECMO patients (%) | 0·0 |
| Length of Stay (days)* | 35·7 ± 32·2 |
| Length of Stay of patients with high-flow nasal oxygen (days) | 14·2 ± 5·8 |
| Length of Stay of ECMO patients (days) | 70·7 ± 36·9 |
| Percentage of all patients who received intermittently muscle relaxants (%) | 30·4 |
| Percentage of ECMO patients who received intermittently muscle relaxants (%) | 100·0 |
| Percentage of all patients who received intermittently norepinephrine and vasopressin (%) | 30·4 |
| Percentage of ECMO patients who received intermittently norepinephrine and vasopressin (%) | 66·7 |
| APACHE II | 18·0 ± 9·4 |
| SOFA all patients | 6·3 ± 4·9 |
| SOFA of patients with high-flow nasal oxygen (no intubation) | 2·2 ± 1·3 |
| SOFA of patients with ECMO | 11·0 ± 5·3 |
| COVID-19 symptoms - no. (%) | |
| Dyspnea | 19 (82·6) |
| Cough | 18 (78·3) |
| Sore throat | 3 (13) |
| Fever | 22 (95·7) |
| Myalgia | 9 (39·1) |
| Exhaustion | 13 (56·5) |
| Coexisting conditions - no. (%) | |
| COPD | 3 (13·0) |
| Asthma | 1 (4·3) |
| Other lung disease | 3 (13·0) |
| Pre-obesity | 10 (43·5) |
| Obesity | 8 (34·8) |
| Arterial hypertension | 18 (78·3) |
| Diabetes mellitus Type 2 | 9 (39·1) |
| Coronary heart disease | 2 (8·7) |
| HIV, transplantation or immuno-supressive medications | 2 (8·7) |
| Patients | 10 |
| Age (years) | 70·4 ± 10·8 |
| Sex - Male (%) | 80 |
| BMI, kg/m2 | 28·4 ± 4·5 |
| Mean duration of symptoms before admission (days) | 7·2 ± 4·3 |
| Mean duration of symptoms before intubation (days) | 8·7 ± 4·2 |
| Hospital mortality rate (%) | 40·0 |
| Length of Stay (days)* | 38·3 ± 26·1 |
| Percentage of patients who received intermittently muscle relaxants (%) | 40·0 |
| Percentage of patients who received intermittently norepinephrine and vasopressin (%) | 30·0 |
| APACHE II | 17·8 ± 9·4 |
| SOFA | 3·9 ± 2·9 |
| Patients | 7 |
| Age (years) | 61·4 ± 15·8 |
| Sex - Male (%) | 57·1 |
| BMI, kg/m2 | 30·0 ± 6·5 |
| Mean duration of symptoms before admission (days) | 5·7 ± 2·6 |
| Mean duration of symptoms before intubation (days) | 6·7 ± 2·7 |
| Hospital mortality rate (%) | 42·9 |
| Length of Stay (days) | 56·3 ± 32·9 |
| Percentage of patients who received intermittently muscle relaxants (%) | 28·6 |
| Percentage of patients who received intermittently norepinephrine and vasopressin (%) | 28·6 |
| APACHE II | 20·7 ± 8·8 |
| SOFA | 5·7 ± 5·2 |
| Respiratory rate/ min | 16·0 ± 2·6 |
| Patients | 9 |
| Age (years) | 62·0 ± 14·2 |
| Sex - Male (%) | 66 |
| BMI, kg/m2 | 30·4 ± 6·5 |
| Mean duration of symptoms before admissions (days) | 6·7 ± 4·8 |
| Mean duration of symptoms before intubation (days) | 7·2 ± 4·8 |
| Hospital mortality rate (%) | 55·6 |
| Length of Stay (days) | 50·4 ± 34·9 |
| Percentage of patients who received intermittently muscle relaxants (%) | 55·6 |
| Percentage of patients who received intermittently norepinephrine and vasopressin (%) | 44·4 |
| APACHE II | 26·2 ± 6·5 |
| SOFA | 7·4 ± 4·9 |
| Mean time to first prone positioning (days) | 3 ± 3·9 |
| Duration of each prone positioning (hours) | 15·4 ± 2·5 |
Values are means ± SD. COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; APACHE II, Acute Physiology And Chronic Health Evaluation II; SOFA, Sepsis-related organ failure assessment score. APACHE II and SOFA score were obtained at admissions day. #One patient is still hospitalized and thus excluded from the hospital mortality rate.
One patient is still hospitalized and excluded from hospital mortality rate and length of stay analyses.
PEEP trials in early COVID-19 ARDS patients.
| Patient: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | Mean | SD | Median | Inter-quartile range |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0·7 | 0·8 | 0·7 | 0·75 | 0·7 | 0·8 | |||||
| 24 | 13 | 24 | 18 | 20 | 18 | 24 | |||||
| 22.0 | 11.0 | 20.0 | 18.0 | 16.0 | 16.0 | 22.0 | |||||
| 6·3 | 6·1 | 7·0 | 6·7 | 5·5 | 7·2 | 6·4 | |||||
| 13.0 | 15.0 | 13.0 | 15.0 | 22.0 | 16.0 | 16.0 | |||||
| 59·6 | 45·0 | 79.0 | 64·8 | 30.0 | 41·9 | 60·1 | |||||
| 8.0 | 9.0 | 7.0 | 11.0 | 17·2 | 11.0 | 9.0 | |||||
| 6·9 | 7·9 | 4·5 | 7·1 | 11·8 | 8·4 | 6·1 | |||||
| 3·1 | 0·3 | 0·8 | 10.0 | 10·8 | 2·6 | 7·9 | |||||
| 0·5 | 0·4 | 0·3 | 0·35 | 0·5 | 0·6 | 0·35 | |||||
| 85.0 | 85·0 | 71·0 | 65·3 | 81·7 | 79·6 | 88·7 | |||||
| 59.0 | 44·0 | 50·0 | 47·3 | 73·4 | 45·0 | 48·4 | |||||
| 170·0 | 242·9 | 236·7 | 186·6 | 163·4 | 132·7 | 253·4 |
Results of PEEP trial shows the optimal PEEP as determined by decremental PEEP trial, and corresponding respiratory system mechanics and arterial blood gas analyses for all seven patients, as well as means, standard deviations (SD), median, and interquartile range.
Fig. 2Invasive positive pressure ventilation with high PEEP improves oxygenation and reduces opacities in chest x-rays. The left boxplots (A) present the PaO2/FiO2 ratio two hours prior and six hours post intubation from the ten patients of Subset 1. Scoring of pulmonary opacities was performed, showing a reduction in pulmonary opacity scores with positive pressure ventilation (B). Representative chest x-ray images of one patient obtained before intubation (C) and after onset of mechanical ventilation (D) are shown. Whiskers indicate the 5th and 95th percentile. The cross within the box marks the mean. A two-sided paired t-test (A), and a Wilcoxon signed-rank test (B) was performed. **p<0·01, ***p<0·001.
Fig. 3Prone positioning improves oxygenation. PaO2/FiO2 ratio was measured in nine patients subjected to prone positioning (Subset 3). Group data show PaO2/FiO2 ratio after the first prone positioning (PP) relative to the previous supine position (SP) (A), after the first three PP maneuvers vs. the three preceding SPs (B), and for all prone positions (C). Whiskers indicate the 5th and 95th percentile. The cross within the box marks the mean. A two-sided paired t-test was performed. *p<0·05, **p<0·01.